$0.91
-0.05 (-5.59%)
Open$0.96
Previous Close$0.96
Day High$0.96
Day Low$0.90
52W High$2.23
52W Low$0.85
Volume—
Avg Volume201.6K
Market Cap20.02M
P/E Ratio—
EPS$-0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,353.9% upside
Current
$0.91
$0.91
Target
$31.32
$31.32
$21.60
$31.32 avg
$37.71
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.32M | 9.26M | 9.19M |
| Net Income | 712.1K | 643.5K | 610.9K |
| Profit Margin | 7.6% | 7.0% | 6.7% |
| EBITDA | 971.8K | 983.2K | 961.2K |
| Free Cash Flow | 631.5K | 606.6K | 819.9K |
| Rev Growth | +16.1% | +5.9% | +8.5% |
| Debt/Equity | 1.16 | 1.10 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |